KIF5B/RET fusion
MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
Premium
European Commission Approves Vertex's Personalized CF Drug Kalydeco